Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 43

1.

Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity.

Yaccoby S, Pearse RN, Johnson CL, Barlogie B, Choi Y, Epstein J.

Br J Haematol. 2002 Feb;116(2):278-90.

PMID:
11841428
2.

RANK-Fc: a therapeutic antagonist for RANK-L in myeloma.

Sordillo EM, Pearse RN.

Cancer. 2003 Feb 1;97(3 Suppl):802-12. Review.

3.

RANK ligand and osteoprotegerin in myeloma bone disease.

Sezer O, Heider U, Zavrski I, Kühne CA, Hofbauer LC.

Blood. 2003 Mar 15;101(6):2094-8. Epub 2002 Nov 7. Review.

4.

Advances in biology and therapy of multiple myeloma.

Barillé-Nion S, Barlogie B, Bataille R, Bergsagel PL, Epstein J, Fenton RG, Jacobson J, Kuehl WM, Shaughnessy J, Tricot G.

Hematology Am Soc Hematol Educ Program. 2003:248-78. Review.

PMID:
14633785
5.
6.

Novel aspects of osteoclast activation and osteoblast inhibition in myeloma bone disease.

Heider U, Hofbauer LC, Zavrski I, Kaiser M, Jakob C, Sezer O.

Biochem Biophys Res Commun. 2005 Dec 16;338(2):687-93. Epub 2005 Oct 3. Review.

PMID:
16216218
7.

Significance of macrophage inflammatory protein-1 alpha (MIP-1alpha) in multiple myeloma.

Terpos E, Politou M, Viniou N, Rahemtulla A.

Leuk Lymphoma. 2005 Dec;46(12):1699-707. Review.

PMID:
16263571
9.

Bone complications in multiple myeloma.

Berenson JR, Rajdev L, Broder M.

Cancer Biol Ther. 2006 Sep;5(9):1082-5. Epub 2006 Sep 20. Review.

PMID:
16969119
10.

[Cytokines in bone diseases. Cytokines and myeloma bone disease].

Abe M.

Clin Calcium. 2010 Oct;20(10):1474-80. doi: CliCa101014741480. Review. Japanese.

PMID:
20890028
11.

Anti-tumour activity of bisphosphonates in human myeloma cells.

Shipman CM, Rogers MJ, Apperley JF, Graham R, Russell G, Croucher PI.

Leuk Lymphoma. 1998 Dec;32(1-2):129-38. Review.

PMID:
10037008
12.

Myeloma bone disease.

Callander NS, Roodman GD.

Semin Hematol. 2001 Jul;38(3):276-85. Review.

PMID:
11486316
13.

Targeting the interplay between myeloma cells and the bone marrow microenvironment in myeloma.

Abe M.

Int J Hematol. 2011 Oct;94(4):334-43. doi: 10.1007/s12185-011-0949-x. Epub 2011 Oct 18. Review.

PMID:
22005835
14.

Zoledronic acid exerts its antitumor effect in multiple myeloma interfering with the bone marrow microenvironment.

Corso A, Ferretti E, Lazzarino M.

Hematology. 2005 Jun;10(3):215-24. Review.

PMID:
16019470
15.

Challenging the current approaches to multiple myeloma-related bone disease: from bisphosphonates to target therapy.

Tassone P, Tagliaferri P, Rossi M, Calimeri T, Bulotta A, Abbruzzese A, Caraglia M, Neri P.

Curr Cancer Drug Targets. 2009 Nov;9(7):854-70. Review.

PMID:
20025573
16.

Targeting the bone microenvironment in multiple myeloma.

Roodman GD.

J Bone Miner Metab. 2010 May;28(3):244-50. doi: 10.1007/s00774-009-0154-7. Epub 2010 Feb 4. Review.

PMID:
20127498
17.

Cell fusion and hyperactive osteoclastogenesis in multiple myeloma.

Silvestris F, Ciavarella S, Strippoli S, Dammacco F.

Adv Exp Med Biol. 2011;714:113-28. doi: 10.1007/978-94-007-0782-5_5. Review.

PMID:
21506010
18.

Homing behaviour of the malignant cell clone in multiple myeloma.

Van Riet I, Vanderkerken K, de Greef C, Van Camp B.

Med Oncol. 1998 Sep;15(3):154-64. Review.

PMID:
9819792
19.

Multiple myeloma: present and future.

Hussein MA, Juturi JV, Lieberman I.

Curr Opin Oncol. 2002 Jan;14(1):31-5. Review.

PMID:
11790977
20.

Tumor-host cell interactions in the bone disease of myeloma.

Fowler JA, Edwards CM, Croucher PI.

Bone. 2011 Jan;48(1):121-8. doi: 10.1016/j.bone.2010.06.029. Epub 2010 Jul 13. Review.

Items per page

Supplemental Content

Write to the Help Desk